Drug interactions
Indacaterol-glycopyrronium + Osilodrostat
Severity: Moderate
Indacaterol-glycopyrronium and Osilodrostat: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Osilodrostat can prolong the QT interval, and beta-2 agonists such as indacaterol may also affect repolarisation, particularly with hypokalemia. Combined use may increase the risk of ventricular arrhythmias in susceptible patients.
What this interaction means in plain words
Indacaterol-glycopyrronium and Osilodrostat can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Indacaterol-glycopyrronium belongs to Respiratory; Osilodrostat belongs to Endocrine.
Why it happens
Additive QT prolongation, with possible beta-agonist related hypokalemia contributing.
What to do
Obtain a baseline ECG and monitor QTc, potassium and magnesium during combined use. Correct electrolyte abnormalities before and during therapy.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Indacaterol-glycopyrronium and Osilodrostat, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Other interactions of Osilodrostat
Frequently asked questions
Can I take Indacaterol-glycopyrronium with Osilodrostat?
MediHelp rates the interaction as moderate. Indacaterol-glycopyrronium and Osilodrostat can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Osilodrostat can prolong the QT interval, and beta-2 agonists such as indacaterol may also affect repolarisation, particularly with hypokalemia. Combined use may increase the risk of ventricular arrhythmias in susceptible patients.
How serious is the interaction between Indacaterol-glycopyrronium and Osilodrostat?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain a baseline ECG and monitor QTc, potassium and magnesium during combined use. Correct electrolyte abnormalities before and during therapy.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
